News | February 06, 2014

3-D Mapping Biopsies Improve Prostate Cancer Detection

February 6, 2014 — Ultrasound-guided biopsies miss prostate cancers that are detected by the slightly more expensive and slightly more invasive 3-D mapping biopsies. A 2006 study compared ultrasound-guided biopsy of 180 men diagnosed with early stage prostate cancer to 3-D mapping biopsy. The study showed nearly a quarter of patients were upgraded to a more clinically significant stage of disease after 3-D mapping found pockets of cancer missed by the first technique. A University of Colorado Cancer Center study reports the locations of these most-missed pockets of prostate cancer.
 
"There are three major reason we perform these 3-D mapping biopsies in the clinic: First, a man may have rising PSA despite a series of negative biopsies and so want a more detailed opinion,” said . “Second, a man may prefer additional reassurance that watching and waiting rather than treatment is the best course of action Al Barqawi, M.D., investigator at the CU Cancer Center, associate professor at the CU School of Medicine and the paper's senior author. Third, a man may pursue focal therapy in which only the cancerous sections of the prostate are removed and so need accurate information on the position of his cancer." 
 
In a 3-D mapping biopsy technique, needle biopsies are taken 5mm apart across the x-, y- and z-axes of a three-dimensional grid through the prostate. Barqawi has performed over 600 of these procedures.
 
The current study enrolled 161 men with a mean age of 61.6 years who had been diagnosed with low-stage prostate cancer by ultrasound-guided biopsy. The study performed 3-D mapping biopsies at a mean 192 days after the first and compared the results. Overall, ultrasound-guided biopsy found an average of 1.38 cancerous zones per patient, whereas 3-D mapping biopsy found 3.33 per patient.
 
The follow-up findings from the 3-D mapping study resulted in upgrading the severity of many of these seemingly low-grade cancers. Specifically, after first biopsy, 7.5 percent of patients had been graded Gleason 7, the lowest grade at which treatment is considered "medium risk" and for which treatment is a reasonable option. After second biopsy, the percentage increased to 25. After first biopsy, no patients had been scored above Gleason 7, and after 3-D mapping biopsy, 4 percent were found to have Gleason 8, and 2 percent had Gleason 9.
 
"What we hoped to discover in this study is exactly where cancer is being missed by ultrasound-guided biopsy,” Barqawi said.
 
Of these 161 total cases, cancer was found in the left-mid section of the prostate 62 times after it had been missed by ultrasound-guided biopsy. Likewise, 3-D mapping found 62 unreported cancers in the right-mid section and 41 undetected cancers in the left-apex zone.
 
"This study adds to our knowledge about the interface and best uses of these two techniques. The cost and invasiveness of 3-D mapping biopsy make it inappropriate for screening,” Barqawi said, “but our message is that with the confirmation or strong suspicion of cancer, 3-D mapping biopsy offers a much more accurate assessment of the location, stage and risk.”
 
For more information: www.ucdenver.edu

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
Prostate Brachytherapy Shows Low Incidence of Short-Term Complications
News | Brachytherapy Systems | October 31, 2018
A new analysis of nearly 600 men receiving brachytherapy for prostate cancer shows overall procedure-related...
Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer. ASTRO 2018 #ASTRO2018 #ASTRO #ASTRO18

Biomarker blood test accurately confirms remission in non-smoker with HPV-associated oral cancer.

News | Radiation Oncology | October 30, 2018
October 30, 2018 — A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to
Prostate Radiotherapy Outcomes Better for African-Americans Than Caucasian Patients according to a study presented at ASTRO 2018. #ASTRO #ASTRO18 #ASTRO2018
Feature | Prostate Cancer | October 30, 2018
October 30, 2018 — While popular beliefs and population data suggest that African-American men are at higher risk of
Combined Therapy Including Pelvic Lymph Node Radiation Provides Significant Benefit for Prostate Cancer Patients - late breaking study presented at ASTRO 2018.
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...
Boston Scientific Closes Acquisition of Augmenix Inc.
News | Prostate Cancer | October 17, 2018
Boston Scientific Corp. announced the close of its acquisition of Augmenix Inc., developer of the SpaceOAR Hydrogel...
New Guideline for Prostate Cancer Supports Shortened Radiation Therapy
News | Prostate Cancer | October 12, 2018
Three prominent medical societies issued a new clinical guideline for physicians treating men with early-stage prostate...